Scuto et al., Blood 2008
(Precursor Cell Lymphoblastic Leukemia-Lymphoma) :
We investigated the mechanism of action of LBH589 , a novel broad-spectrum HDAC inhibitor belonging to the hydroxamate class, in Philadelphia chromosome negative ( Ph ( - ) ) acute lymphoblastic leukemia ( ALL )
Mannava et al., Blood 2012
(Multiple Myeloma) :
Instead, KLF9 levels correlated with bortezomib dependent inhibition of histone deacetylases (HDAC) and were increased by the HDAC inhibitor LBH589 ( panobinostat )
Vilas-Zornoza et al., Leukemia 2012
(Precursor Cell Lymphoblastic Leukemia-Lymphoma) :
Here, we analyzed the therapeutic effect of LBH589 , a class I-II HDAC inhibitor , in acute lymphoblastic leukemia ( ALL )